Results for: Drug Development

Rapt Therapeutics, Inc. (RAPT) saw its stock plummet by over 46% on Monday after the company announced the termination of its zelnecirnon (RPT193) program due to a serious adverse event (SAE) of liver injury. The program was being investigated in two Phase 2 clinical trials for asthma and atopic dermatitis, but both trials were placed on FDA clinical hold in February 2024. This decision followed a liver injury requiring a transplant in a patient participating in the atopic dermatitis trial. The company subsequently closed both studies and discontinued the zelnecirnon program, highlighting the challenges faced in drug development due to safety concerns. Rapt Therapeutics is now focusing on developing next-generation CCR4 compounds with improved safety profiles.

The global pharmaceutical chemicals market is poised for significant growth, projected to reach US$ 339.3 billion by 2031, driven by factors such as rising healthcare spending, advancements in drug development, and increasing prevalence of chronic diseases. North America dominates the market, while Asia Pacific shows promising growth potential. Key players in the sector are focusing on innovative solutions and strategic acquisitions to capitalize on this expanding market.

Aditum Bio and Leads Biolabs have partnered to form Oblenio Bio, a company focused on developing LBL-051, a first-of-its-kind tri-specific T-cell engager antibody. This innovative therapy targets both CD19 and BCMA, aiming to provide superior efficacy and durability for treating a wide range of autoimmune diseases.

The Fragment-Based Drug Discovery (FBDD) market is rapidly expanding, driven by the growing need for innovative and efficient drug development approaches. This method offers key advantages over traditional drug discovery methods, including enhanced chemical diversity and higher hit rates. FBDD is particularly valuable for targeting challenging proteins that are often difficult to address using conventional methods. This article explores the key drivers of the FBDD market, its segmentation, and regional insights.

The global clinical trial packaging market is projected to reach a substantial $9.12 billion by 2034, driven by a surge in drug trials, patient-centric packaging demands, and the integration of advanced technologies. North America currently dominates the market, but the Asia-Pacific region is poised for rapid growth.

GC Biopharma and Novelty Nobility have partnered to develop antibody-based therapies for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that can lead to blindness. The collaboration aims to leverage both companies’ expertise to create a new treatment with improved efficacy and safety compared to existing options.

A new study suggests that semaglutide, the active ingredient in popular diabetes and weight-loss drugs Wegovy and Ozempic, could reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes. Researchers at Case Western Reserve University School of Medicine found that patients taking semaglutide had a significantly lower risk of developing Alzheimer’s compared to those on other diabetes medications.

Evotec SE (EVO) stock surged on Wednesday after the company announced significant advancements in its strategic partnership with Bristol-Myers Squibb Company (BMY). This collaboration, focused on developing a molecular glue-based pipeline, has yielded a $50 million program-based payment for Evotec, driven by the expansion of the pipeline beyond oncology. The partnership, which began in 2018 and was extended for another 8 years in 2022, continues to deliver on its promise of innovative drug development.

BofA Securities has upgraded Tyra Biosciences, a clinical-stage biotech company, from Neutral to Buy, citing promising preclinical data for their drug TYRA-300 and its potential to treat urothelial carcinoma. The upgrade comes ahead of the presentation of phase 1/2 data at the ENA Meeting next week. BofA’s bullish outlook is based on the drug’s differentiated safety profile compared to existing treatments, leading to projected sales of $175 million by 2030.

Tevogen Bio Holdings Inc. (TVGN) has announced a bullish revenue forecast for its oncology pipeline, projecting $1 billion in revenue during its launch year and a cumulative 5-year estimate of $10 billion to $14 billion. This optimistic outlook stems from the company’s innovative drug development model, which aims to accelerate and streamline the process. The company’s stock surged in response to this news, reflecting investor confidence in its potential.